Jens D. Lundgren
Expertise in
15
conditions

Jens D. Lundgren

Copenhagen, DK 
Expertise in
15
conditions
Copenhagen, DK 
OverviewLocationsClinical Research

Overview

Jens Lundgren practices in Copenhagen, Denmark. Mr. Lundgren is highly rated in 15 conditions, according to our data. His top areas of expertise are HIV/AIDS, Cytomegalovirus Infection, Severe Acute Respiratory Syndrome (SARS), Bone Marrow Transplant, and Lung Transplant.

His clinical research consists of co-authoring 461 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Gender
Male

Locations

Copenhagen, Denmark
Other Locations
Hvidovre, Denmark
Skejby, Denmark
Herlev, 8632, Denmark

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

An International Observational Study to Characterize Adults Who Are Hospitalized With Influenza or Other Targeted Respiratory Viruses
An International Observational Study to Characterize Adults Who Are Hospitalized With Influenza or Other Targeted Respiratory Viruses
Enrollment Status: Completed
Publish Date: October 21, 2024
An International Observational Study of Outpatients With SARS-CoV-2 Infection
An International Observational Study of Outpatients With SARS-CoV-2 Infection
Enrollment Status: Completed
Publish Date: August 16, 2022
Intervention Type: Other
An International Multicenter, Adaptive, Randomized Double-Blind, Placebo-Controlled Trial of the Safety, Tolerability and Efficacy of Anti-Coronavirus Hyperimmune Intravenous Immunoglobulin for the Treatment of Adult Hospitalized Patients at Onset of Clinical Progression of COVID-19
An International Multicenter, Adaptive, Randomized Double-Blind, Placebo-Controlled Trial of the Safety, Tolerability and Efficacy of Anti-Coronavirus Hyperimmune Intravenous Immunoglobulin for the Treatment of Adult Hospitalized Patients at Onset of Clinical Progression of COVID-19
Enrollment Status: Completed
Publish Date: April 04, 2022
Intervention Type: Other, Drug, Biological
Study Drugs: Hyperimmune immunoglobulin to SARS-CoV-2, Remdesivir
Study Phase: Phase 3
A Phase 3, Multicenter, Randomized, Open-label, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Treatment Compared to Investigator-assigned Treatment in Transplant Recipients With Cytomegalovirus (CMV) Infections That Are Refractory or Resistant to Treatment With Ganciclovir, Valganciclovir, Foscarnet, or Cidofovir
A Phase 3, Multicenter, Randomized, Open-label, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Treatment Compared to Investigator-assigned Treatment in Transplant Recipients With Cytomegalovirus (CMV) Infections That Are Refractory or Resistant to Treatment With Ganciclovir, Valganciclovir, Foscarnet, or Cidofovir
Enrollment Status: Completed
Publish Date: November 03, 2021
Intervention Type: Drug
Study Phase: Phase 3
An International Prospective Observational Study to Assess the Characteristics and Outcomes of Post-transplant Patients Treatment for C. Difficile Infections
An International Prospective Observational Study to Assess the Characteristics and Outcomes of Post-transplant Patients Treatment for C. Difficile Infections
Enrollment Status: Completed
Publish Date: November 01, 2019
An International Observational Study to Characterize Adults With Influenza or Other Targeted Respiratory Viruses
An International Observational Study to Characterize Adults With Influenza or Other Targeted Respiratory Viruses
Enrollment Status: Completed
Publish Date: August 18, 2017
View 5 Less Clinical Trials

457 Total Publications

The diagnostic value of soluble Epstein-Barr Virus BZLF1 protein (sZEBRA) in the Detection of Post-transplant lymphoproliferative Disease (PTLD) among Solid Organ (SOT) and Haematopoietic Cell (HSCT) Transplant Recipients.
The diagnostic value of soluble Epstein-Barr Virus BZLF1 protein (sZEBRA) in the Detection of Post-transplant lymphoproliferative Disease (PTLD) among Solid Organ (SOT) and Haematopoietic Cell (HSCT) Transplant Recipients.
Journal: The Journal of infectious diseases
Published: June 02, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Lundgren's expertise for a condition
ConditionClose
View All 12 Advanced Conditions
View All 47 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile